Lifecare ASA

As of June 30, 2026, Lifecare ASA carries a market capitalization of 10.44M, placing it among publicly traded companies globally. Its enterprise value stands at 7.58M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Lifecare ASA's next confirmed earnings release is scheduled for November 12, 2026.

As of June 30, 2026, Lifecare ASA has 407.71M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 591.63, and the price-to-book ratio stands at 2.13.

These figures are as of June 30, 2026. The EV/Sales ratio of 856.05 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 7.58M versus a market cap of 10.44M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Lifecare ASA maintains a current ratio of 11.69, meaning it holds 11.7x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Lifecare ASA posted a negative return on equity (ROE) of -205.11, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -165.78, reflecting losses generated across the asset base. The company generates approximately 337.12 in revenue per employee across its workforce of 26.25, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Lifecare ASA recorded an income tax benefit of -41,592.46 rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -10.51M and -10.43M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Lifecare ASA's stock has declined approximately 77.30% over the past 52 weeks. The 50-day moving average sits at 0.03, while the 200-day moving average is 0.04.

Over the twelve months ended June 30, 2026, Lifecare ASA generated 8,849.46 in revenue and converted that into -10.43M in net income, yielding earnings per share of -0.05. EBITDA reached -10.24M, while operating income came in at -10.17M.

As of June 30, 2026, Lifecare ASA holds 3.26M in cash and equivalents against 486,631.76 in total debt, resulting in a net debt position of -3.26M. Total book value stands at 4.91M, with working capital of 3.65M providing operational flexibility.

Lifecare ASA produced -10.26M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -378,668.36 in capital expenditures, free cash flow totaled -10.64M - equivalent to -0.05 per share.

These figures cover the twelve months ended June 30, 2026. The operating margin of -114,905.00 and net profit margin of -117,827.00 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -203.27: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -106.42, meaning Lifecare ASA raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Lifecare ASA's most recent stock split took place on January 5, 2026.

As of June 30, 2026, Lifecare ASA has an Altman Z-Score of 2.32, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.